EMG
TVTX icon

ETF Managers Group’s Travere Therapeutics TVTX Stock Holding History

ETF Managers Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$143K Buy
+6,378
New +$136K ﹤0.01% 613

Other funds holding TVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ETF Managers Group's TVTX Position: Q1 2023 in Review

ETF Managers Group opened a new position in Travere Therapeutics (TVTX) in Q1 2023: 6,378 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #613 among its holdings.

174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

  • ETF Managers Group held 6,378 shares of Travere Therapeutics worth $143K as of Q1 2023.
  • Travere Therapeutics was a new ETF Managers Group position in Q1 2023.
  • Travere Therapeutics made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #613 holding.
  • 174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.